Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Perceived high costs, inconsistent insurance coverage, and drug shortages have created barriers ... or overweight (body mass ...

The national use of weight loss drugs like Ozempic and Wegovy more than doubled as bariatric surgery frequency dropped by ...

New studies to be presented at the American Heart Association meeting focus on disparities in Wegovy prescriptions and ...

For Sprackling, the key to consumers benefiting from GLP-1 medications is responsible use rather than viewing them as a quick ...

Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

There are many mechanisms at work here, but the blood sugar increase is probably secondary to the weight gain, rather than ...

Deaths from cardiovascular disease have surged among adults ages 25 to 64 living in rural areas, a new study shows.

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...